Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00231920
Status:
COMPLETED
Last Update Posted:
2011-08-12
First Post:
2005-09-30
Brief Title:
Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Prospective Pilot Safety Study Administering Two Doses of Inactivated Influenza Vaccine to Infants 10-22 Weeks of Age
Status:
COMPLETED
Status Verified Date:
2006-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study proposes to enroll 50 young infants ages 10 to 22 weeks Each of the fifty infants will receive two 025mL doses of preservative-free Fluzone given a minimum of 28 days apart but no more than 42 days apart Preservative-free Fluzone will not be administered at the same time as other routine vaccines Approximately 2-3mLs of blood sample will be obtained prior to the first vaccination approximately 4 weeks after the second vaccination and 6 months after the second vaccination for the measurement of immune response The primary purpose of this study is twofold 1 To determine the safety of administering two doses of preservative-free Fluzone to young infants and 2 To determine the capability of inducing an immune response of administering two doses of preservative-free Fluzone to young infants
Detailed Description:
Influenza virus is an important global cause of morbidity and mortality Influenza A or B viruses cause epidemics of disease almost every winter in the United States with an average of 36000 deaths and 114000 hospitalizations each year during 1990s superscript 1 Children have the highest rates of infection while adults greater than 50 years of age have the highest mortality rates superscript 2 Influenza however is associated with hospitalizations in young infants In a survey of the Tennessee Medicaid database over many years Neuzil et al reported hospitalization rates in children less than 6 months of age that were much higher than in older children and the rates approached those over 65 years of age superscript 3 This is a prospective phase l open-label self-contained four visits over a period of 7 months pilot study of 50 healthy infants aged 10-22 weeks with history of up-to-date routine immunizations to assess safety and immunogenicity of administering 2 pediatric doses with a minimum 4 weeks apart of 025 ml of trivalent Influenza vaccine Fluzone Each of the 50 infants will receive two 025mL doses of preservative free Fluzone given a minimum of 28 days apart but no more than 42 days apart Preservative-free Fluzone will not be administered at the same time as other routine vaccines Approximately 2-3 mLs of venous blood will be obtained prior to the first vaccination approximately 4 weeks after the second vaccination and 6 months after the second vaccination for the measurement of neutralization and HAI titers Infants will be closely monitored during the influenza season for respiratory symptoms fever or other influenza-like illnesses They will be seen during these episodes and nasal washes will be collected for a viral screen that will include culture for influenza virus respiratory syncytial virus RSV adenovirus and parainfluenza virus and rapid test for influenza and RSV Blood collected at the follow up visit 6 months after the second dose of Fluzone will be used to measure post season antibody titers to strains of influenza A and B
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None